Madetko et al. (36) suggest that factors potentially enhancing the effectiveness of immunotherapy include cognitive impairment, non-classical phenotypes, HLA-DQB *05:01 (+) and HLA-DRB *10:01 (−) status, IgG1 subtype, and inflammatory changes in the cerebrospinal fluid. Here, HLA-DRB1 is linked to Cognitive impairment.